Results 241 to 250 of about 280,420 (306)

RETRACTION: Beta3-Adrenergic Receptor Activation Alleviates Cardiac Dysfunction in Cardiac Hypertrophy by Regulating Oxidative Stress. [PDF]

Oxid Med Cell Longev
Cellular Longevity OMA.
europepmc   +1 more source

Second‐generation prokineticin PKR1 receptor agonists: Advancing cardioprotection against chemotherapy‐induced toxicity

British Journal of Pharmacology, EarlyView.
IS39, a novel non‐peptide PKR1 agonist, confers cardioprotection against doxorubicin‐induced toxicity. IS39 activates PKR1‐mediated pro‐survival signalling in cardiomyocytes, reducing reactive oxygen species (ROS), DNA damage and fibrosis markers. In vivo, IS39 preserves cardiac geometry and function in mice exposed to chronic doxorubicin challenge ...
Anais Audebrand, Simone Brogi, Mustafa Tezeren, Andrea Tafi, Omer H. Ocak, Hasan Koyuncu, Igor Tetko, Laurent Désaubry, Canan G. Nebigil   +8 more
wiley   +1 more source

A circular RNA derived from the ryanodine receptor 2 locus controls cardiac hypertrophy and calcium handling. [PDF]

Cell Mol Life Sci
Pan W, Hunkler HJ, Chatterjee S, Lu D, Riedel I, Gietz A, Xiao K, Fuchs M, Neufeldt D, Kraft T, Huang CK, Cushman S, Bührke A, Schmidt A, Mohr E, Weber N, Bär C, Thum T.   +17 more
europepmc   +1 more source

Myeloid MyD88 Mediates Macrophage Infiltration and Activation in Ang II-Induced Cardiac Hypertrophy. [PDF]

J Cell Mol Med
Lin K, Yang N, Hu C, Luo W, Huang P, Liang G, Wang Y.   +6 more
europepmc   +1 more source

Activation of FoxO1 prevents and reverses cardiac hypertrophy from diverse stimuli. [PDF]

J Mol Cell Cardiol
Martin TG, Langer SJ, Crocini C, Chung E, Leinwand LA.   +4 more
europepmc   +1 more source

Corrigendum to "Wogonin Inhibits Cardiac Hypertrophy by Activating Nrf-2-Mediated Antioxidant Responses". [PDF]

Cardiovasc Ther
europepmc   +1 more source

Special Issue "Cellular and Molecular Biology of Cardiac Hypertrophy and Heart Failure: Pathogenesis, Diagnostics and Treatment". [PDF]

Int J Mol Sci
Karmazyn M.
europepmc   +1 more source

Protosappanin A protects against pathological cardiac hypertrophy by inhibiting oxidative stress and NLRP3 inflammasome-mediated pyroptosis via activation of the Nrf2 signaling pathway. [PDF]

Front Cardiovasc Med
He Q, Zheng Y, Yan X, Lv S, Yu B.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Experimental Cardiac Hypertrophy

New England Journal of Medicine, 1970
STUDIES on the process by which enlargement of the heart occurs1 2 3 4 have been aided by developments in molecular biology.
openaire   +2 more sources

Endothelin and Cardiac Hypertrophy

Life Sciences, 1997
Cardiac hypertrophy is a commonly observed complication of a variety of cardiovascular diseases. As well as mechanical stresses such as pressure overload, several humoral factors may contribute to the development of cardiac hypertrophy. In the early 1990s, endothelin-1 (ET-1) was found to induce cardiomyocyte hypertrophy in cultured neonatal rat ...
openaire   +2 more sources